A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Inclusion Criteria: * Patients of either sex aged 12 years or older. * Females of childbearing potential should use appropriate contraception. Women of childbearing potential must have a negative pregnancy test at screening and baseline visits. * Patient and legal representative(s), if applicable, has provided written informed consent. * Patient has congenital ichthyosis of either lamellar or X-Linked subtype. * Patient has two contralateral comparable Treatment Areas (e.g., each arm is affected and treatments areas can be applied equally). * Patient is, except for their ichthyosis, in good general health. Exclusion Criteria: * Patient is pregnant or breast feeding, or is planning to become pregnant during the study. * Patient has inflammatory skin disease unrelated to ichthyosis. * Patient is currently using concomitant retinoid therapy, within two weeks (topical) or 12 weeks (oral) of Visit 2/Baseline. * Patient is currently taking concomitant immunosuppressive drugs, including systemic corticosteroids, within two weeks of Visit 2/Baseline. * Patient is currently enrolled in an investigational drug or device study. * Patient has used an investigational drug or investigational device treatment within 30 days prior to Visit 2/Baseline. * Patient is unable to communicate or cooperate with the investigator due to language problems, impaired cerebral function, or physical limitations. * Patient is known to be noncompliant or is unlikely to comply with the requirements of the …